Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya

Cervix Cancer Clinical Trial

Official title: Self-administered Artesunate Pessaries for Treatment of Cervical Precancer in Kenya

Status Recruiting

Clinical Trial Summary

To investigate the use of self-administered artesunate vaginal pessaries as treatment for cervical precancer in low and middle-income countries (LMIC). The central hypothesis of this study is that self-administered intravaginal Artesunate will be safe, and result in a clinical response among both HIV-positive and HIV-negative women with cervical precancer in LMICs.

Clinical Trial Description

Despite being preventable, cancer of the cervix is a leading cause of cancer death in Kenya and other low- and middle-income countries (LMIC). Cervical cancer can be prevented if early changes in the cervix, called cervical precancer, are detected through screening, and adequately treated. Cervical precancer treatment includes a surgical procedure called Loop Electrosurgical Excision Procedure (LEEP), which removed the involved area of the cervix.

In countries like Kenya, this LEEP procedure is only available in referral hospitals which have trained consultants, and hence is difficult to access for most women who live in rural areas and away from tertiary facilities. Additionally, the LEEP procedure also increases the chance of a woman not being able to carry a pregnancy to full term, because the cervix is shorter after the procedure. For these reasons, alternative treatments, including self-administered treatments such as Artesunate are being investigated as alternative cervical precancer treatment that can be self-administered. ;

Related Conditions & MeSH terms

• Cervical Precancer
• Cervix Cancer
• Cervix Neoplasm
• Precancerous Conditions
• Uterine Cervical Dysplasia
• Uterine Cervical Neoplasms

• NCT number: NCT06165614
• Study type: Interventional
• Source: UNC Lineberger Comprehensive Cancer Center
• Contact: Chemtai P Mungo, MD, MPH, MSc
• Phone: 919-966-5280
• Email: cmungo@email.unc.edu
• Status: Recruiting
• Phase: Phase 1
• Start date: March 4, 2024
• Completion date: December 2025